Elevating the Future
of Cancer Care with
Alpha Theranostics.
ACCELERATE.EU is a project pioneering the development of novel radiotheranostic pairs featuring the alpha-emitting isotope astatine-211 (211At) to target aggressive cancers like pancreatic, breast, and brain cancer. By combining innovative therapies with a new generation of compact cyclotrons, the project aims to enhance cancer treatment outcomes and make these advanced therapies more accessible in clinical settings.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101173001. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.
Essential facts about the project driving the expansion
of Alpha therapy in Europe- 17Partners
- 9countries
- 5Years
- 16M€ budget
- 100Manpower
- 3Industry
partners - 3Unmet
clinical needs - 30+Patients
treated
With a strong
representation of
EU expertise in
nuclear medicine
This collaboration brings together 17 leading European institutions and companies across 9 countries, blending academic expertise with industrial innovation.
Complementary expertise across EU members
Resilient & strategic EU initiative to stand as a frontrunner in targeted alpha therapy
Flagship ecosystem setting the ground for a broader partner adoption and larger patient benefits
enable 211At production network
clinical needs
to boost alpha theranostic uptake
over 5 years
- Early supply
- Ligand & radiolabeling
- Preclinical & co-clinical
- Clinical trials
- Production scale-up
Transversal collaboration: 5 axes of
innovation to accelerate targeted
alpha-therapy uptake across EU
The project is set to transform the landscape of cancer care by pioneering the development of novel radiotheranostic solutions to address unmet clinical needs. At the heart of this initiative is 211At, a highly promising alpha-emitting radioisotope with the potential to treat aggressive cancers such as triple-negative breast cancer, pancreatic cancer, and glioblastoma. The project will focus on developing and testing new therapeutic agents, ensuring a robust and sustainable infrastructure for 211At production and treatment.
Early supply
1.5 M€
Ligand &
radiolabeling
1.9 M€
Preclinical &
co-clinical
1.8 M€
Clinical trials
3.2 M€
Production
scale-up
7.6 M€
- Early supply
- Ligand & radiolabeling
- Preclinical & co-clinical
- Clinical trials
- Production scale-up
Consolidated contributions
along five work packages
Transition from research production capacity to industrial supply chain
Cross sectorial partnership: industry, biotech, universities, hospitals, patient association,…
Accelerated translation from experimental to clinical implementation
Risk-mitigated breakthroughs for
severe unmet clinical needs
By integrating the entire value chain—from bench to bedside—Accelerate.EU aims to streamline the supply of 211At across Europe, ensuring that patients have timely access to this innovative treatment. The project will also explore co-clinical approaches, where clinical studies run in parallel with preclinical studies, enhancing the ability to identify patients who are most likely to benefit from 211At therapy
bench...
- PancreasPDACI = 0.09 ‰SR = 9 %NTR1TRL 21.8 M€Preclinical
- BreastTNBCI = 0.17 ‰SR = 12 %FAPiTRL 33.2 M€Co-clinical + Phase I
- BrainGBMI = 0.04 ‰SR = 5 %SubPTRL 41.2 M€Phase I
bedside
- Early supply
- Ligand & radiolabeling
- Preclinical & co-clinical
- Clinical trials
IBA onboards all along 211At value
chain for a total 8.5M€ invest with
20% funding from EC
The Accelerate.EU project, a groundbreaking EUR 16 million initiative, has been officially launched with the ambitious goal of establishing a resilient and strategic European autonomy in alpha therapies. This five-year project aims to enhance patient access to cutting-edge cancer treatments by creating a complete value chain for the production and clinical application of the alpha-emitting isotope Astatine-211 (211At).
A significant industry investment
in synergy with public research
The project has secured EUR 8 million in funding from the European Commission under the Innovative Health Initiative (IHI), matched by an equivalent in-kind contribution from industry partners.
In-kind
Industry contributors:
- 6.8 M€
- 0.7 M€
- 0.5 M€
Funding
Funding from the European commission under the Innovatibe Health Initiative (IHI)
- Early supply
- Ligand & radiolabeling
- Preclinical & co-clinical
- Clinical trials
- Production scale-up
A public-private co-leadership to
steer and pace collective efforts…
As the industry leader of the Accelerate.EU initiative, IBA will facilitate the development of a production network to enable greater access to targeted alpha therapy across the EU through the development of a new alpha-machine cyclotron as an in-kind contribution. IBA will also work in close collaboration with the Jules Bordet Institute, the academic and clinical Accelerate.EU coordinator, to manage the project.
- Ligand & radiolabeling
- Production scale-up
- Preclinical & co-clinical
- Clinical trials
From an ecosystem paving
the way to a rapid targeted
alpha therapy uptake
Investment typology
- Investment typology
- Goods
- Internally invoiced services
- Equipment depreciation
- Travel & Networking
- Subcontracting
Dedicated At-211 Runs Every Week
to Support the Accelerate.EU Project
1000 hours
of cumulated
cyclotron irradiation
1 run per week dedicated to the Accelerate.EU project